{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Combination+Group&page=13", "query": { "intervention": "Combination Group", "page": 13 }, "page_size": 10 }, "pagination": { "page": 13, "page_size": 10, "total_count": 2795, "total_pages": 280, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Combination+Group&page=14&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Combination+Group&page=12&page_size=10" }, "source": "remote", "last_synced_at": "2026-11-14T18:53:28.938Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01482390", "title": "A Study of Mericitabine in Combination With Telaprevir and Peginterferon Alfa-2a / Ribavirin in Participants With Chronic Hepatitis C", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "Ribavirin", "type": "DRUG" }, { "name": "Mericitabine", "type": "DRUG" }, { "name": "Peginterferon Alfa-2a", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" }, { "name": "Telaprevir", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 80, "start_date": "2011-11-30", "completion_date": "2014-01-31", "has_results": false, "last_update_posted_date": "2017-04-24", "last_synced_at": "2026-11-14T18:53:28.938Z", "location_count": 15, "location_summary": "Birmingham, Alabama • Long Beach, California • Sacramento, California + 12 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Long Beach", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "New Haven", "state": "Connecticut" } ], "official_url": "https://clinicaltrials.gov/study/NCT01482390" }, { "nct_id": "NCT01183013", "title": "30 Week Parallel Group Comparison Study of Linagliptin + Pioglitazone (5+15, 5+30 and 5+45 mg) qd Versus Respective Monotherapies, Followed by a Comparison of 5mg+30mg and 5mg+45mg Versus Respective Monotherapies in Type 2 Diabetes for up to 54 Weeks", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes Mellitus, Type 2" ], "interventions": [ { "name": "Pioglitazone 15 mg", "type": "DRUG" }, { "name": "Pioglitazone 45 mg", "type": "DRUG" }, { "name": "Pioglitazone 30 mg", "type": "DRUG" }, { "name": "Linagliptin 5mg / Pioglitazone 45 mg FDC", "type": "DRUG" }, { "name": "Linagliptin 5mg / Pioglitazone 30 mg FDC", "type": "DRUG" }, { "name": "Linagliptin 5mg", "type": "DRUG" }, { "name": "Linagliptin 5mg / Pioglitazone 15 mg FDC", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "18 Years to 80 Years" }, "enrollment_count": 936, "start_date": "2010-08", "completion_date": "2013-02", "has_results": true, "last_update_posted_date": "2014-10-20", "last_synced_at": "2026-11-14T18:53:28.938Z", "location_count": 74, "location_summary": "Birmingham, Alabama • Montgomery, Alabama • Muscle Shoals, Alabama + 60 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Montgomery", "state": "Alabama" }, { "city": "Muscle Shoals", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Mesa", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT01183013" }, { "nct_id": "NCT00649025", "title": "A Study Comparing the Safety and Efficacy of Fluticasone and Formoterol Combination (FlutiForm™) With Fluticasone or Flovent to Treat Moderate to Severe Asthma in Adolescents and Adults", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Asthma" ], "interventions": [ { "name": "FlutiForm 250/10", "type": "DRUG" }, { "name": "SKP-Fluticasone", "type": "DRUG" }, { "name": "Flovent Fluticasone HFA", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "SkyePharma AG", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": null, "sex": "ALL", "summary": "12 Years and older" }, "enrollment_count": 438, "start_date": "2008-03", "completion_date": "2008-10", "has_results": false, "last_update_posted_date": "2010-08-27", "last_synced_at": "2026-11-14T18:53:28.938Z", "location_count": 21, "location_summary": "Scottsdale, Arizona • Tempe, Arizona • Encinitas, California + 18 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tempe", "state": "Arizona" }, { "city": "Encinitas", "state": "California" }, { "city": "Long Beach", "state": "California" }, { "city": "Orange", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00649025" }, { "nct_id": "NCT00612040", "title": "Comparison of Two NN1250 Formulations Versus Insulin Glargine, All in Combination With Insulin Aspart in Subjects With Type 1 Diabetes", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Diabetes", "Diabetes Mellitus, Type 1" ], "interventions": [ { "name": "insulin degludec", "type": "DRUG" }, { "name": "insulin glargine", "type": "DRUG" }, { "name": "insulin aspart", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novo Nordisk A/S", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 178, "start_date": "2008-01", "completion_date": "2008-06", "has_results": true, "last_update_posted_date": "2017-03-03", "last_synced_at": "2026-11-14T18:53:28.938Z", "location_count": 9, "location_summary": "Walnut Creek, California • Honolulu, Hawaii • Idaho Falls, Idaho + 5 more", "locations": [ { "city": "Walnut Creek", "state": "California" }, { "city": "Honolulu", "state": "Hawaii" }, { "city": "Idaho Falls", "state": "Idaho" }, { "city": "Des Moines", "state": "Iowa" }, { "city": "Hyattsville", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00612040" }, { "nct_id": "NCT01333943", "title": "Saphenous Nerve Block Versus Femoral Nerve Block for Total Knee Arthroplasty", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Total Knee Arthroplasty" ], "interventions": [ { "name": "Study Group: Experimental", "type": "PROCEDURE" }, { "name": "Control Group", "type": "PROCEDURE" } ], "intervention_types": [ "PROCEDURE" ], "sponsor": "Hospital for Special Surgery, New York", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "18 Years to 90 Years" }, "enrollment_count": 94, "start_date": "2011-03", "completion_date": "2011-11", "has_results": true, "last_update_posted_date": "2022-05-11", "last_synced_at": "2026-11-14T18:53:28.938Z", "location_count": 1, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01333943" }, { "nct_id": "NCT02385110", "title": "Alemtuzumab or Tocilizumab in Combination With Etoposide and Dexamethasone for the Treatment of Adult Patients With Hemophagocytic Lymphohistiocytosis", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Leukemia" ], "interventions": [ { "name": "Alemtuzumab", "type": "DRUG" }, { "name": "Etoposide", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Phone Call", "type": "BEHAVIORAL" }, { "name": "Tocilizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG", "BEHAVIORAL" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2015-09-23", "completion_date": "2023-01-24", "has_results": true, "last_update_posted_date": "2024-01-17", "last_synced_at": "2026-11-14T18:53:28.938Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02385110" }, { "nct_id": "NCT01337726", "title": "Combined Illness Management and Psychotherapy in Treating Depressed Elders", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Depression", "Heart Failure", "Chronic Obstructive Pulmonary Disease" ], "interventions": [ { "name": "Combined Psychotherapy and Illness Management", "type": "BEHAVIORAL" }, { "name": "Illness Management Only", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "University of Iowa", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "55 Years", "maximum_age": null, "sex": "ALL", "summary": "55 Years and older" }, "enrollment_count": 226, "start_date": "2011-02", "completion_date": "2016-10", "has_results": false, "last_update_posted_date": "2017-04-05", "last_synced_at": "2026-11-14T18:53:28.938Z", "location_count": 2, "location_summary": "Iowa City, Iowa", "locations": [ { "city": "Iowa City", "state": "Iowa" }, { "city": "Iowa City", "state": "Iowa" } ], "official_url": "https://clinicaltrials.gov/study/NCT01337726" }, { "nct_id": "NCT00094276", "title": "Intervention for Improving Asthma Care for Minority Children in Head Start", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Asthma", "Lung Diseases" ], "interventions": [ { "name": "Facilitated Asthma Communication Intervention (FACI)", "type": "BEHAVIORAL" }, { "name": "Breathmobile intervention", "type": "BEHAVIORAL" } ], "intervention_types": [ "BEHAVIORAL" ], "sponsor": "Johns Hopkins University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "2 Years", "maximum_age": "6 Years", "sex": "ALL", "summary": "2 Years to 6 Years" }, "enrollment_count": 336, "start_date": "2004-09", "completion_date": "2009-06", "has_results": false, "last_update_posted_date": "2018-04-25", "last_synced_at": "2026-11-14T18:53:28.938Z", "location_count": 1, "location_summary": "Baltimore, Maryland", "locations": [ { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00094276" }, { "nct_id": "NCT01073189", "title": "Intra-Renal Therapy of Diuretic Unresponsive Acute Kidney Injury", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Kidney Failures, Acute" ], "interventions": [ { "name": "Intra-Renal Fenoldopam", "type": "DRUG" }, { "name": "Furosemide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Southeast Renal Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2010-04", "completion_date": "2011-01", "has_results": false, "last_update_posted_date": "2016-03-28", "last_synced_at": "2026-11-14T18:53:28.938Z", "location_count": 1, "location_summary": "Chattanooga, Tennessee", "locations": [ { "city": "Chattanooga", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT01073189" }, { "nct_id": "NCT03507491", "title": "Nab-paclitaxel in Combination with Gemcitabine for Pediatric Relapsed and Refractory Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Cancer" ], "interventions": [ { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Nab-paclitaxel", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "6 Months", "maximum_age": "30 Years", "sex": "ALL", "summary": "6 Months to 30 Years" }, "enrollment_count": 24, "start_date": "2018-08-27", "completion_date": "2024-02-02", "has_results": false, "last_update_posted_date": "2024-10-04", "last_synced_at": "2026-11-14T18:53:28.938Z", "location_count": 4, "location_summary": "Aurora, Colorado • St. Petersburg, Florida • Atlanta, Georgia + 1 more", "locations": [ { "city": "Aurora", "state": "Colorado" }, { "city": "St. Petersburg", "state": "Florida" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Kansas City", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT03507491" } ] }